![New York Stem Cell Foundation Announces Partnership with Parkinson's Progression Markers Initiative - New York Stem Cell Foundation New York Stem Cell Foundation Announces Partnership with Parkinson's Progression Markers Initiative - New York Stem Cell Foundation](https://nyscf.org/wp-content/uploads/2013/10/7fff74282c8cdbb70e66b6fc74f9ad94_XL.jpg)
New York Stem Cell Foundation Announces Partnership with Parkinson's Progression Markers Initiative - New York Stem Cell Foundation
![Frontiers | Trajectory Analysis of Orthostatic Hypotension in Parkinson's Disease: Results From Parkinson's Progression Markers Initiative Cohort Frontiers | Trajectory Analysis of Orthostatic Hypotension in Parkinson's Disease: Results From Parkinson's Progression Markers Initiative Cohort](https://www.frontiersin.org/files/Articles/762759/fnagi-13-762759-HTML/image_m/fnagi-13-762759-g001.jpg)
Frontiers | Trajectory Analysis of Orthostatic Hypotension in Parkinson's Disease: Results From Parkinson's Progression Markers Initiative Cohort
Over the last 10 years, volunteers in the Parkinson's Progression Markers Initiative (PPMI) have helped expand our understandi
Did you know that if you printed PPMI data, it would reach to the moon and back? Our Parkinson's Progression Markers Initiative (PPMI) shares its robust... | By The Michael J. Fox
![Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study - The Lancet Neurology Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study - The Lancet Neurology](https://www.thelancet.com/cms/attachment/0dda957a-5bbe-4ce4-9f7e-d6d277883585/gr1_lrg.jpg)
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study - The Lancet Neurology
![Assessment of heterogeneity and disease onset in the Parkinson's Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study | medRxiv Assessment of heterogeneity and disease onset in the Parkinson's Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2023/03/01/2023.02.27.23286156/F1.large.jpg)
Assessment of heterogeneity and disease onset in the Parkinson's Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study | medRxiv
![Sample size estimation for clinical trials in de novo Parkinson's disease (PD): Results from the Parkinson's Progression Markers Initiative (PPMI) Study - MDS Abstracts Sample size estimation for clinical trials in de novo Parkinson's disease (PD): Results from the Parkinson's Progression Markers Initiative (PPMI) Study - MDS Abstracts](https://www.mdsabstracts.org/wp-content/uploads/2017/05/0037-002207_001.png)
Sample size estimation for clinical trials in de novo Parkinson's disease (PD): Results from the Parkinson's Progression Markers Initiative (PPMI) Study - MDS Abstracts
![Evaluation of the PREDIGT score's performance in identifying newly diagnosed Parkinson's patients without motor examination | npj Parkinson's Disease Evaluation of the PREDIGT score's performance in identifying newly diagnosed Parkinson's patients without motor examination | npj Parkinson's Disease](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41531-022-00360-5/MediaObjects/41531_2022_360_Fig1_HTML.png)